In:
British Journal of Pharmacology, Wiley, Vol. 174, No. 14 ( 2017-07), p. 2261-2272
Abstract:
The therapeutic management of hepatitis B virus (HBV) infections remains challenging, and novel antiviral strategies are urgently required. The HBV transbody, a monoclonal antibody (MAb) against human HBcAg coupled with the trans‐activator of transcription protein transduction domain (TAT PTD), was previously shown to possess cell‐penetrating ability and potent antiviral activity in vitro . The purpose of the present study was to evaluate the antiviral activity of the HBcMAb‐TAT PTD conjugate in vivo in a duck model of HBV. Experimental Approach Female Peking ducks were injected i.p. with 0.03‐0.3 mg·kg −1 ·day −1 of the DHBV transbody (DHBcMAb‐TAT PTD conjugate) for 30 days. Serum DHBV DNA levels and liver DHBV DNA and covalently closed circular DNA (cccDNA) loads were determined at scheduled time points. Immunohistological examination of DHBcAg in the duck liver was also performed. Key Results The DHBV transbody significantly reduced the serum and liver DHBV DNA levels at doses of 0.1 and 0.3 mg·kg −1 ·day −1 and liver cccDNA levels at a dose of 0.3 mg·kg −1 ·day −1 after 30 days of treatment. The suppressive effects of the DHBV transbody at 0.3 mg·kg −1 ·day −1 on the serum and liver DHBV DNA and liver cccDNA levels remained significant, even at 15 days after treatment cessation. Similarly, immunohistochemistry of liver sections revealed decreased DHBcAg levels within hepatocytes 15 days after treatment termination. Conclusions and Implications The DHBV transbody inhibits DHBV replication and possesses potent anti‐DHBV activities in vivo . The cell‐permeable antibody against the virus core antigen may be developed as a novel treatment for patients with hepadnavirus infections.
Type of Medium:
Online Resource
ISSN:
0007-1188
,
1476-5381
Language:
English
Publisher:
Wiley
Publication Date:
2017
detail.hit.zdb_id:
2029728-2
SSG:
15,3
